Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05579392 · ClinicalTrials.gov registry record · NA
A Randomized Crossover Trial of Bright Light Therapy in Crohn's Disease on Intestinal Barrier Homeostasis
A NA study of Inflammatory Bowel Disease, sponsored by Rush University Medical Center.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 2
- Study locations
NCT05579392: Recruiting NA study of Inflammatory Bowel Disease, sponsored by Rush University Medical Center.
NCT05579392 is a NA study of Inflammatory Bowel Disease that is actively recruiting participants, run by Rush University Medical Center. The registered enrollment target is 30 participants, below the 403-participant average among 28 other Inflammatory Bowel Disease trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05579392, a NA study of Inflammatory Bowel Disease, is actively recruiting participants, sponsored by Rush University Medical Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
Crohn's Disease (CD) and Ulcerative Colitis (UC), collectively known as inflammatory bowel disease (IBD), are two of the most significant chronic conditions of the gastrointestinal tract (GIT) and affects over 1.5 million individuals in the U.S. Recently, there has been an increased understanding of the importance of sleep and sleep disruption in IBD as a potentially modifiable risk factor. We, therefore, hypothesize that intervening with morning bright light therapy (BLT) in IBD patients with CM will decrease intestinal permeability and pro-inflammatory cytokines, positively impact intestinal microbiota, and improve quality of life (QoL).
Primary Outcome
Participants will ingest a sugar cocktail at Visits 2-5 and complete a urine collection. Measurement of urinary sugars is done using gas chromatography is used to calculate intestinal permeability.
Conditions Studied
Interventions
- DEVICE Bright Light Therapy
- DEVICE Placebo Retimer Device
Study Locations (2)
Illinois
- Rush University Medical Center - Chicago
South Carolina
- Medical University of South Carolina - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-09-22 |
| Est. Completion | 2026-05-31 |
| Phase | NA |
What NCT05579392 shows while recruiting
NCT05579392 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 403-participant average among 28 other Inflammatory Bowel Disease trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Inflammatory Bowel Disease appearing as the primary indexed condition, and to 2 interventions - of which Bright Light Therapy is the first listed.
NCT05579392 reports a single indexed study location in Illinois, South Carolina.
Frequently Asked Questions
What is clinical trial NCT05579392 about?
NCT05579392 is a clinical study titled "A Randomized Crossover Trial of Bright Light Therapy in Crohn's Disease on Intestinal Barrier Homeostasis". Crohn's Disease (CD) and Ulcerative Colitis (UC), collectively known as inflammatory bowel disease (IBD), are two of the most significant chronic conditions of the gastrointestinal tract (GIT) and affects over 1.5 million individuals in the U.S. Recently, there has been an increased understanding of...
What is the current status of trial NCT05579392?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2022-09-22. Estimated completion is 2026-05-31.
What conditions does trial NCT05579392 study?
This clinical trial studies the following conditions: Inflammatory Bowel Disease.
What interventions are being tested in trial NCT05579392?
The interventions under investigation include: Bright Light Therapy (DEVICE), Placebo Retimer Device (DEVICE).
Who is sponsoring clinical trial NCT05579392?
This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05579392 being conducted?
This trial has 2 study locations across Illinois, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Inflammatory Bowel Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05579392's enrollment target sits among peer trials
30 25th of 28 higher than 3 of 28 other Inflammatory Bowel Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Inflammatory Bowel Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Impact of Morning Light Therapy in IBD
RECRUITING · NA
-
Effect of Mediterranean Diet in Inflammatory Bowel Disease
RECRUITING · NA
-
The Influence of a Fasting Mimicking Diet on Ulcerative Colitis
RECRUITING · NA
-
Testing the Impact of Measurement-Based Care on Quality of Life and Disease Management Among Veterans With Inflammatory Bowel Disease
RECRUITING · NA
-
Treatment of Depressed Adolescents With Physical Illness
COMPLETED · NA
-
Pneumococcal Vaccination in Patients With Inflammatory Bowel Disease
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI